USZ0 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Sharp Revenue ReboundThe substantial FY2026 revenue rebound indicates improved commercial traction and stronger customer demand compared with the prior year. If the higher sales level persists, it could provide a broader base for operating leverage, reinvestment, and eventual margin improvement.
Improving EPS TrendPositive EPS growth signals improvement in per-share earnings compared with the relevant prior period, even though the company remains loss-making overall. Continued progress would strengthen the investment case if it develops into sustained earnings improvement rather than a temporary recovery.
Expanded Asset BaseThe larger asset base shows that the company expanded its recorded resources during FY2026. This may support greater operating capacity and commercial development over the medium term, although the benefit will depend on whether those assets generate stronger profitability and cash returns.
Bears Say
Persistent UnprofitabilityNegative gross profit and a deeply negative net margin indicate that current sales are not yet producing an economically sustainable business model. Without meaningful improvement in unit economics and operating efficiency, revenue growth may continue to require funding rather than translate into durable earnings.
Negative Shareholders' EquityNegative equity materially reduces financial flexibility and indicates that accumulated obligations exceed the recorded value attributable to shareholders. This can make future funding more important, increase recapitalization risk, and constrain the company’s ability to absorb further losses independently.
Ongoing Cash BurnSustained negative operating and free cash flow shows that the business is not currently funding its operations from internally generated cash. Continued burn can increase reliance on external capital, limit investment flexibility, and weaken resilience if losses persist over coming quarters.
Stemcell United Ltd. News
USZ0 FAQ
What was Stemcell United Ltd.’s price range in the past 12 months?
Currently, no data Available
What is Stemcell United Ltd.’s market cap?
Stemcell United Ltd.’s market cap is €1.46M.
When is Stemcell United Ltd.’s upcoming earnings report date?
Stemcell United Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 179 days.
How were Stemcell United Ltd.’s earnings last quarter?
Stemcell United Ltd. released its earnings results on Aug 31, 2026. The company reported $0 earnings per share for the quarter.
Is Stemcell United Ltd. overvalued?
According to Wall Street analysts Stemcell United Ltd.’s price is currently Undervalued.
Does Stemcell United Ltd. pay dividends?
Stemcell United Ltd. does not currently pay dividends.
What is Stemcell United Ltd.’s EPS estimate?
Stemcell United Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Stemcell United Ltd. have?
Stemcell United Ltd. has 2,353,484,600 shares outstanding.
What happened to Stemcell United Ltd.’s price movement after its last earnings report?
Stemcell United Ltd. reported an EPS of $0 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Stemcell United Ltd.?
Currently, no hedge funds are holding shares in DE:USZ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stemcell United Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stemcell United Ltd.
BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. The company's diverse product range features both unprocessed and refined bird's nest offerings, alongside marine botanicals like Caulerpa Lentillifera (sea grapes) and various seaweeds. These products are utilized across multiple industries, including food, nutrition, healthcare, dietary supplements, cosmetics, and personal care. Headquartered in Melbourne, Australia, the company was founded in 1984 and transitioned to its current name, BPH Global Ltd, in June 2023, having previously been known as Stemcell United Limited.
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Regeneus Ltd.
―